105 related articles for article (PubMed ID: 19017757)
1. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
2. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
Cetani F; Banti C; Pardi E; Borsari S; Viacava P; Miccoli P; Torregrossa L; Basolo F; Pelizzo MR; Rugge M; Pennelli G; Gasparri G; Papotti M; Volante M; Vignali E; Saponaro F; Marcocci C
Endocr Connect; 2013; 2(4):186-95. PubMed ID: 24145611
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid carcinoma arising from four-gland hyperplasia.
Kauffmann RM; Juhlin CC; Fohn LE; Broome JT; Phay JE
Endocr Pract; 2011; 17(2):e37-42. PubMed ID: 21247853
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining with CD117 and PGP9.5 of excised vestibular tissue from patients with neuroproliferative vestibulodynia.
Drian A; Goldstein SW; Kim NN; Goldstein AS; Hartzell-Cushanick R; Yee A; Goldstein I
J Sex Med; 2024 Apr; 21(5):479-493. PubMed ID: 38521973
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid tumors in the 5th edition of the WHO Classification of Tumors of the Endocrine Organs.
J D
Cesk Patol; 2024; 60(1):68-70. PubMed ID: 38697830
[TBL] [Abstract][Full Text] [Related]
6. Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment.
Juhlin CC
Endocr Pathol; 2024 Mar; 35(1):84-87. PubMed ID: 38363524
[No Abstract] [Full Text] [Related]
7. Parathyroid carcinoma.
Khurana AS; Munjal M; Narad M
Indian J Otolaryngol Head Neck Surg; 2001 Jan; 53(1):53-5. PubMed ID: 23119753
[No Abstract] [Full Text] [Related]
8. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues.
Naccarato AG; Marcocci C; Miccoli P; Bonadio AG; Cianferotti L; Vignali E; Cipollini G; Viacava P
J Endocrinol Invest; 1998 Mar; 21(3):136-41. PubMed ID: 9591207
[TBL] [Abstract][Full Text] [Related]
10. The significance of an immunohistochemical marker-based panel in assisting the diagnosis of parathyroid carcinoma.
Hu Y; Mo S; Xiao J; Cui M; Zheng Q; Chen T; Chang X; Liao Q
Endocrine; 2024 Feb; ():. PubMed ID: 38340242
[TBL] [Abstract][Full Text] [Related]
11. Genomic and transcriptomic profiling reveal molecular characteristics of parathyroid carcinoma.
Jo SY; Hong N; Lee S; Jeong JJ; Won J; Park J; Kim GJ; Kim SK; Kim S; Rhee Y
Exp Mol Med; 2023 May; 55(5):886-897. PubMed ID: 37121965
[TBL] [Abstract][Full Text] [Related]
12. Molecular and Clinical Spectrum of Primary Hyperparathyroidism.
Jha S; Simonds WF
Endocr Rev; 2023 Sep; 44(5):779-818. PubMed ID: 36961765
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).
Wang X; Zhang N; Li M; Hong T; Meng W; Ouyang T
Oncol Lett; 2023 Mar; 25(3):123. PubMed ID: 36844618
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Epigenetic Alterations in Parathyroid Neoplasms.
Miratashi Yazdi SA; Nazar E
Iran J Pathol; 2022; 17(4):395-405. PubMed ID: 36532647
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.
Uljanovs R; Sinkarevs S; Strumfs B; Vidusa L; Merkurjeva K; Strumfa I
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805976
[TBL] [Abstract][Full Text] [Related]
16. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.
Nosé V; Gill A; Teijeiro JMC; Perren A; Erickson L
Endocr Pathol; 2022 Mar; 33(1):197-227. PubMed ID: 35285003
[TBL] [Abstract][Full Text] [Related]
17. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis.
Ciregia F; Cetani F; Pardi E; Soggiu A; Piras C; Zallocco L; Borsari S; Ronci M; Caruso V; Marcocci C; Mazzoni MR; Lucacchini A; Giusti L
Cancer Genomics Proteomics; 2021; 18(6):781-796. PubMed ID: 34697069
[TBL] [Abstract][Full Text] [Related]
19. Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience.
De Pasquale L; Bulfamante AM; Felisati G; Castellani L; Ghilardi G; Saibene AM
Int J Endocrinol; 2021; 2021():5397941. PubMed ID: 34659402
[TBL] [Abstract][Full Text] [Related]
20. Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.
Juhlin CC; Erickson LA
Endocr Pathol; 2021 Mar; 32(1):17-34. PubMed ID: 33269427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
